In treating HER2-positive gastric cancer, the median OS of capecitabine and oxaliplatin (CapeOx) combined with lapatinib and CapeOx plus placebo was 12.2 months and 10.5 months, respectively, and there was no significant difference. Here, ERBB2 is linked to gastric cancer.